Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.

Abstract

The cytotoxic drug ifosfamide is subject to an extensive metabolism. This study reports the results of a pharmacokinetic study of the parent drug and the two dechloroethylated metabolites in 22 patients on a 10-day continuous infusion of ifosfamide. Ifosfamide causes a substantial induction of the enzymes responsible for its metabolism, resulting in a two-fold increase of the clearance. The maximal IF concentration is reached after 24 h, after which the concentration decreases to a steady-state. The dechloro-ethylated compounds can be detected in the plasma about 8 h after the start of the infusion with plasma half-lives longer than for IF. Urinary excretion studies revealed that at least a quarter of the IF dose is excreted as inactive compounds.

• Authors: G P Kaijser, H J Keizer, J H Beijnen, A Bult, W J Underberg
• Journal: Anticancer research (Anticancer Res) 1996 Sep-Oct Vol. 16 Issue 5B Pg. 3247-57 ISSN: 0250-7005 [Print] Greece
• PMID: 8920799 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents, Alkylating
• dechloroethylcyclophosphamide
• Cyclophosphamide
• dechloroethylifosfamide
• Ifosfamide

Topics

• Adult
• Aged
• Antineoplastic Agents, Alkylating (administration & dosage, blood, pharmacokinetics)
• Cyclophosphamide (analogs & derivatives, pharmacokinetics)
• Female
• Humans
• Ifosfamide (administration & dosage, analogs & derivatives, blood, pharmacokinetics)
• Male
• Middle Aged
• Neoplasms (drug therapy, metabolism)